Azotemia Treatment & Management

Updated: Mar 09, 2023
  • Author: Moro O Salifu, MD, MPH, MBA, MACP; Chief Editor: Vecihi Batuman, MD, FASN  more...
  • Print

Pharmacologic and Supportive Therapy

Prerenal azotemia

If volume depletion is due to free water loss, the serum sodium is often elevated by 10 mEq/L from baseline. The amount of fluid replacement in liters—that is, the free water deficit—can be estimated from serum sodium (mg/dL) and patient weight (kg) as follows:

[(Na/140) – 1] × 0.5 × weight

The volume of fluid to be administered is equal to the sum of the free-water deficit and daily maintenance fluids. Fifty percent of this total volume should be administered in the first 24 hours, and a new calculation should be performed at 24 hours based on new laboratory results.

Maintenance fluid can be roughly estimated at 1.5-2 L/day; however, it can also be estimated from caloric intake since 1 kCal requires 1 mL of water in the metabolic process. Normal caloric intake is about 30 Kcal/kg (low catabolic state requires < 30 kCal/kg and high catabolic state requires > 40 kCal/kg). A 70-Kg person at normal caloric intake requires 2100 Kcal/day or 2.1 L of fluid intake. This volume should be added to the free-water deficit and administered as noted above.

Alternatively, the total free water deficit is usually quite close to the sum of 50% free-water deficit and daily maintenance fluids. Therefore, for all practical purposes, the total free-water deficit can be administered intravenously in 24 hours.

The fluid to be administered should consist of hypotonic solutions such as 0.5% saline or 5% dextrose in water (D5W). Alert patients should be encouraged to drink as much free water as they can tolerate; otherwise, free water can be administered via a nasogastric tube.

Serum sodium should be measured every 6-8 hours, and fluid replacement should be adjusted to avoid a precipitous decline in the serum sodium. To prevent brain edema, the rate of decrease in serum sodium should be no more than 0.7 mEq/h (17 mEq/24 h).

Volume depletion due to blood loss requires IV saline and transfusion to maintain pressure (as well as interventions to halt further loss).

Diarrhea often causes isotonic volume loss that necessitates replacement with normal saline. Normal–anion gap metabolic acidosis occurring with diarrhea warrants infusion of bicarbonate in half-normal saline.

Diuretic-induced volume depletion, especially in the elderly, manifests as dehydration, hyponatremia, [15] and, occasionally, hypokalemia. The treatment of choice consists of normal saline infusion and correction of hypokalemia.

Decreased cardiac output requires optimization of cardiac performance through careful use of the following:

  • Diuretics
  • An angiotensin-converting enzyme (ACE) inhibitor
  • Beta-blockers
  • Nitrates
  • Positive inotropic agents (including dobutamine)
  • When indicated, specific therapy for the cause of impaired cardiac function

When ACE inhibitors are contraindicated because of hyperkalemia, the combination of nitrates and hydralazine offers an alternative. Because these patients tend to have risk factors for macrovascular disease, the diagnosis of ischemic nephropathy or atheroembolic disease should be entertained when kidney function continues to worsen despite optimization of cardiac function.

Reduced effective arterial volume due to systemic shunting can result from sepsis or liver failure. Severe edema, hyponatremia, and hypoalbuminemia often pose management problems. Decreased oncotic pressure, increased vascular permeability, and exaggerated salt and water retention shift the Starling forces toward formation of interstitial fluid. Effective treatment of sepsis with antibiotics and of hypotension with dopamine and norepinephrine is mandated. Crystalloid replacement can be tried, but it often leads to more edema.

In severely hypoalbuminemic patients, salt-poor albumin infusion may be undertaken, but there is no conclusive evidence of benefit from this therapy.

Adequate nutrition and effective treatment of sepsis may improve oncotic pressure and normalize vascular permeability, thereby decreasing the systemic shunting. The net result is improved renal perfusion, decreased salt and water retention, improved urinary output, and reduced edema. In hepatorenal syndrome (HRS), the average survival is 1-2 weeks; however, there is evidence that the kidneys will recover with early liver transplantation. Occasionally, kidney dysfunction is advanced, necessitating replacement therapy.

Intrarenal azotemia

Acute kidney injury

For ischemic or nephrotoxic acute tubular necrosis (ATN) due to shock (hypovolemic, cardiogenic, septic), the initial approach is to restore volume and pressure (with fluid replacement and vasopressors, respectively) and to withdraw any nephrotoxic drugs. [16] If the patient becomes oliguric or anuric from shock, volume in the form of crystalloids should be aggressively administered in boluses (eg, 300 mL every 2 hours, rather than 150 mL every hour). Bolus infusion leads to acute intravascular volume expansion, release of atrial natriuretic peptide from the heart, increased renal blood flow, and natriuresis, all of which favor recovery from ATN compared with slow intravenous hydration.

If at least 2 L of fluids have been administered in a relatively short period (approximately 12 hours) with no improvement in urine output, a trial of high-dose intravenous furosemide (100-160 mg) can be tried, prior to preparation for renal replacement. This approach, called “tank and blast” in shock, also known as "Furosemide Stress Test", [17] is clinically useful. In one small study, hemodynamic and renal support with a continuous infusion of noradrenaline (0.06-0.12 μg/kg/min) and furosemide (10-30 mg/hr) induced polyuria and reversed ATN to nonoliguric acute kidney injury (AKI) in 11 of 14 cancer patients who had severe sepsis and multiorgan dysfunction syndrome. [18] If the patient does not respond to this approach within 6 hours, dialysis or continuous renal replacement therapy should be considered as soon as possible.

If the patient responds by restoration of urine output to greater than 30 mL/h, continue the appropriate amounts of intravenous fluids, vasopressors, and as-needed diuretics to maintain the desired fluid balance (negative, positive, or match intake to output).

This approach is not indicated in nonshock patients with AKI. Nonshock patients with AKI require maintenance fluids, if needed, and avoidance of nephrotoxicity.

In both scenarios, early initiation of renal replacement therapy if azotemia sets in provides a better prognosis than late initiation.

Albumin can be administered in combination with high-dose furosemide to enhance the diuretic effect of furosemide. The use of albumin in this context is not for volume expansion; rather, it allows more furosemide to be bound to albumin for delivery to the organic anion transporter in the kidney, thereby enabling more furosemide to enter the tubule than would otherwise do so.

Although this approach is widely used, research on the combination of albumin and a loop diuretic has principally been on its use for improving diuretic-resistant edema in patients with nephrotic syndrome. [19] Other therapies that have not been conclusively shown to be beneficial are renal-dose dopamine and synthetic atrial natriuretic peptide.

The kidney failure phase usually lasts 7-21 days if the primary insult can be corrected. Postischemic polyuria can be seen in the recovery phase and represents an attempt to excrete excess water and solute. Saline may be replaced (75% of output) as a maintenance fluid, owing to salt wasting during this phase, and to allow the patient to lose excess water retained while the patient was oliguric. Hypokalemia may result from the saline diuresis, so potassium should be replaced. Recovery is marked by the return of blood urea nitrogen (BUN) and creatinine levels to near-baseline values.

Acute interstitial nephritis is managed by withdrawing the offending nephrotoxin and avoiding further nephrotoxic exposure and dehydration. The creatinine level begins to improve within 3-5 days. Kidney biopsy may be indicated if kidney function is severely decreased or azotemia is not improving.

Once the diagnosis is confirmed, a trial of oral prednisone (starting at 1 mg/kg/day and tapering over 6 weeks) or IV pulse methylprednisolone (1 g for 3 days) in severe cases may be considered. If the patient is a poor candidate for biopsy but the diagnosis is strongly suspected, therapy should be started.

Contrast-induced azotemia, which typically becomes evident 3-5 days after exposure, is best prevented by adequate hydration with half-normal saline at 1 mL/kg/h 12 hours before contrast administration and the use of smaller amounts of contrast. Clearly explain the risks of such procedures to the patient.

The benefits of N-acetylcysteine (NAC) and sodium bicarbonate for prevention of contrast-induced azotemia are still being debated. [20, 21, 22] A systematic review and meta-analysis of prevention strategies found that the greatest clinically and statistically significant reduction in contrast-induced nephropathy occurred with NAC in patients receiving low-osmolar contrast media (compared with IV saline) and with statins plus NAC (compared with NAC alone). [23]

The Prevention of Serious Adverse Events Following Angiography (PRESERVE) trial, which included 5177 patients at high risk for renal complications who were undergoing angiography, found no benefit of IV sodium bicarbonate over IV saline or of oral acetylcysteine over placebo. Outcomes measured included the prevention of death, need for dialysis, or persistent decline in kidney function at 90 days, as well as the prevention of contrast-associated AKI. [24]

Chronic kidney disease

It is important that patients with chronic kidney disease (CKD) be referred early to a nephrologist for the management of complications and for the transition to renal replacement therapy (ie, hemodialysis, peritoneal dialysis, renal transplantation). There is some evidence that early referral of patients with CKD improves short-term outcome.

Disease progression can be slowed by means of various maneuvers, such as aggressive control of diabetes, hypertension, and proteinuria; dietary protein and phosphate restriction; and specific therapies for some of the glomerular diseases, such as lupus nephritis. Anemia, hyperphosphatemia, acidosis, and hypocalcemia should be aggressively managed before renal replacement therapy.

Postrenal azotemia

Relief of the obstruction is the mainstay of therapy for postrenal azotemia. In anuria, bladder catheterization is mandatory to rule out bladder neck obstruction, whereas in progressive azotemia, catheterization should be done after the patient has voided to determine the postvoid residual volume. A postvoid residual volume of 100 mL or more suggests obstructive uropathy, and the cause should be further investigated.


Surgical Relief of Obstruction

If hydronephrosis is due to ureteral obstruction, unilateral or bilateral stenting or percutaneous nephrostomy is performed. Recovery of kidney function takes 7-10 days, but kidney function may be severely impaired, necessitating dialysis until such time as partial recovery is adequate for withdrawal of dialysis.

Up to 500-1000 mL/min of postobstructive polyuria can be seen with relief of obstruction. This is an appropriate response and represents an attempt to excrete the excess fluid accumulated during the period of obstruction.

Because of salt wasting during this phase, dehydration and hypokalemia are likely. Thus, two thirds of the urine output should be replaced with half-normal saline and potassium chloride if the patient is hypokalemic. Close monitoring is indicated to prevent hypotension and prerenal azotemia.

Matching the hourly urine output with IV replacement fluid is not recommended, because the excess water retained during the period of obstruction cannot be offloaded if hourly urine output is matched.